Business Context and Reporting Period
This Form 8-K Current Report was filed by Zentalis Pharmaceuticals, Inc. on October 2, 2020, covering events occurring on September 30, 2020, and October 1, 2020. The Company is a Delaware corporation trading on the Nasdaq Global Market under the symbol ZNTL and is classified as an emerging growth company.
Key Financial Metrics and Obligations
This filing does not report revenue, profit, cash flow, or operating margins. It discloses specific financial obligations arising from new agreements:
- Lease Obligation: Base rent of approximately $625,000 per month ($5.30 per square foot) for approximately 117,929 square feet of office and laboratory space in San Diego, California.
- Security Deposit: A letter of credit in the amount of approximately $1.1 million was delivered to the landlord.
- Executive Compensation: Amended severance packages for the CEO, COO, and CFO involving lump-sum payments of base salary and bonuses ranging from 9 to 18 months depending on the timing of termination relative to a change of control.
Material Changes and Agreements
The filing details two primary material changes:
- Entry into a Material Definitive Agreement (Item 1.01): The Company entered into a lease with TPSC IX, LLC for premises at 10275 and 10285 Science Center Drive, San Diego.
- Term: 10 years and 8 months, estimated to commence November 1, 2021, and end June 30, 2032.
- Rent Adjustments: Subject to an annual upward adjustment of 3% starting on the first anniversary of the first rent payment.
- Termination Rights: The Company may terminate the lease after 92 months or 104 months with 12 months' written notice.
- Amended Executive Employment Agreements (Item 5.02): Agreements with CEO Anthony Y. Sun, COO Kevin Bunker, and CFO Melissa Epperly were amended to modify severance terms.
- Standard Termination: Severance includes 12 months of salary/benefits for the CEO and COO, and 9 months for the CFO.
- Change of Control Termination: Enhanced severance applies if termination occurs within 18 months of a change of control (e.g., CEO receives 18 months' salary plus 150% of target bonus).
- Equity Acceleration: All stock awards vest immediately upon termination following a change of control.
Outlook, Risks, and Contingencies
The filing does not provide forward-looking financial guidance or general risk factors. However, the following contingencies are noted:
- Lease Commencement: The lease term and rent payments are contingent upon the completion of tenant improvements or the Company commencing business in the premises, estimated for November 1, 2021.
- Severance Conditions: Executive severance payments are contingent upon the execution of a general release of claims and compliance with restrictive covenants.
Investor Verification Checklist
- Verify the exact commencement date of the lease, as it depends on tenant improvement completion.
- Review the full text of the Lease (Exhibit 10.1) for details on tenant improvement allowances and potential rent adjustments based on utilization.
- Confirm the specific base salaries and target bonus percentages for the CEO, COO, and CFO to calculate potential severance liabilities.
- Assess the impact of the $1.1 million letter of credit on the Company's current liquidity position.